Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

AI-driven enhancer design for gene therapy

Project description

Artificial intelligence takes on nature to discover the secrets of transcription enhancers

All the somatic (non-sex) cells contain all the DNA required to make any of the body's myriad proteins. Obviously, all cells do not make all these proteins. Control of gene expression is regulated in several ways, among them by activation of enhancers. Enhancers are sequences of DNA that, when bound by proteins called transcription factors, boost the transcription of certain genes. Harnessing these could boost the effectiveness of gene therapy. The EU-funded EnhancerDesign project will use AI to figure out enhancer 'logic' and use it for the rational design of synthetic sequences to enhance the transcription of genes in gene therapy. The technology could be widely applicable to therapies for numerous diseases and conditions.

Objective

Gene therapy promises to become a durable clinical option for a whole range of diseases, including monogenic hereditary diseases, cancer and neurodegenerative disorders. However, the development of new gene therapy-based treatments strongly depends on regulatory drivers that provide cell-type specific expression of the transgene, at high enough levels, yet without causing genotoxicity.
The aim of the ERC PoC proposal is to validate a state-of-the-art pipeline, called EnhancerDesign, to design small, strong and cell-type specific human enhancers for gene therapy that will improve specificity and safety, the two major bottlenecks in gene therapy applications. The strength of our EnhancerDesign approach lies in understanding and exploiting the enhancer code by using several state-of-the-art bioinformatics and experimental techniques. We have designed and now aim to validate our pipeline consisting of four parts (1) Single-cell multi-omics profiling; (2) training enhancer models to gain understanding of the enhancer logic; (3) design synthetic sequences in silico; (4) high-throughput enhancer testing.
The project outcome will be twofold. Firstly, the different modules in our pipeline will be further optimized to make the entire pipeline operational to be offered as a service to, or as an asset for collaborative projects with gene therapy companies. Secondly, this project will deliver novel enhancers for a set of chosen cell types, for which no specific enhancers exist, or for which the available enhancers are either too large, too unspecific, or too weak.
Altogether, the development of optimized enhancers by our EnhancerDesign pipeline will allow for improved and cell-type specific expression of a transgene, and has therefore the potential to provide patients with a safer treatment, increased QoL and new treatment options for diseases where gene therapy was not yet an option.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

ERC-POC - Proof of Concept Grant

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) ERC-2020-PoC

See all projects funded under this call

Host institution

VIB VZW
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 150 000,00
Address
SUZANNE TASSIERSTRAAT 1
9052 ZWIJNAARDE - GENT
Belgium

See on map

Region
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Beneficiaries (1)

My booklet 0 0